223 related articles for article (PubMed ID: 31327702)
21. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
22. Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension.
Geenen LW; Baggen VJM; Kauling RM; Koudstaal T; Boomars KA; Boersma E; Roos-Hesselink JW; van den Bosch AE
Heart; 2020 Mar; 106(6):467-473. PubMed ID: 31492701
[TBL] [Abstract][Full Text] [Related]
23. Plasma Growth Differentiation Factor-15 is a Potential Biomarker for Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.
Li G; Li Y; Tan XQ; Jia P; Zhao J; Liu D; Wang T; Liu B
Pediatr Cardiol; 2017 Dec; 38(8):1620-1626. PubMed ID: 28819713
[TBL] [Abstract][Full Text] [Related]
24. Dynamic Changes of Heart Failure Biomarkers in Response to Parabolic Flight.
Jirak P; Wernly B; Lichtenauer M; Paar V; Franz M; Knost T; Abusamrah T; Kelm M; Muessig JM; Bimpong-Buta NY; Jung C
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32423045
[TBL] [Abstract][Full Text] [Related]
25. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study.
Andersson C; Enserro D; Sullivan L; Wang TJ; Januzzi JL; Benjamin EJ; Vita JA; Hamburg NM; Larson MG; Mitchell GF; Vasan RS
Atherosclerosis; 2016 May; 248():245-51. PubMed ID: 26972631
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
27. Prognostic values of novel biomarkers in patients with AL amyloidosis.
Kim D; Lee GY; Choi JO; Kim K; Kim SJ; Ju ES; Jeon ES
Sci Rep; 2019 Aug; 9(1):12200. PubMed ID: 31434944
[TBL] [Abstract][Full Text] [Related]
28. Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease.
Jirak P; Mirna M; Wernly B; Paar V; Thieme M; Betge S; Franz M; Hoppe U; Lauten A; Kammler J; Schulze PC; Lichtenauer M; Kretzschmar D
Minerva Med; 2018 Dec; 109(6):443-450. PubMed ID: 29652038
[TBL] [Abstract][Full Text] [Related]
29. GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.
Stojkovic S; Kaider A; Koller L; Brekalo M; Wojta J; Diedrich A; Demyanets S; Pezawas T
J Cell Mol Med; 2018 Apr; 22(4):2422-2429. PubMed ID: 29397580
[TBL] [Abstract][Full Text] [Related]
30. Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.
Al-Badri A; Tahhan AS; Sabbak N; Alkhoder A; Liu C; Ko YA; Vaccarino V; Martini A; Sidoti A; Goodwin C; Ghazzal B; Beshiri A; Murtagh G; Mehta PK; Quyyumi AA
J Am Heart Assoc; 2020 Apr; 9(8):e015515. PubMed ID: 32301366
[TBL] [Abstract][Full Text] [Related]
31. Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study.
Mirna M; Topf A; Wernly B; Rezar R; Paar V; Jung C; Salmhofer H; Kopp K; Hoppe UC; Schulze PC; Kretzschmar D; Schneider MP; Schultheiss UT; Sommerer C; Paul K; Wolf G; Lichtenauer M; Busch M
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32213894
[No Abstract] [Full Text] [Related]
32. Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
Ishikawa H; Izumiya Y; Shibata A; Ichikawa Y; Yamaguchi T; Yamaguchi Y; Kitada R; Iwata S; Ehara S; Tomita S; Hanatani A; Yoshiyama M
Heart Vessels; 2020 May; 35(5):681-688. PubMed ID: 31741050
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy.
Indumati V; Vijay V; Krishnaswamy D; Rajeshwari V; Ramesh A; Shantala D; Shilpa A
Indian J Tuberc; 2017 Jul; 64(3):206-211. PubMed ID: 28709490
[TBL] [Abstract][Full Text] [Related]
34. Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea.
Bocskei RM; Meszaros M; Tarnoki AD; Tarnoki DL; Kunos L; Lazar Z; Bikov A
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32075014
[No Abstract] [Full Text] [Related]
35. Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.
Hilty MP; Zügel S; Schoeb M; Auinger K; Dehnert C; Maggiorini M
Mediators Inflamm; 2016; 2016():1942460. PubMed ID: 27378823
[TBL] [Abstract][Full Text] [Related]
36. Impact of Left Ventricular Diastolic Dysfunction and Biomarkers on Pulmonary Hypertension in Patients with Severe Aortic Stenosis.
Gumauskienė B; Krivickienė A; Jonkaitienė R; Vaškelytė JJ; Siudikas A; Ereminienė E
Medicina (Kaunas); 2018 Sep; 54(4):. PubMed ID: 30344294
[No Abstract] [Full Text] [Related]
37. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
Jin J; Li YW; He Q
Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
[TBL] [Abstract][Full Text] [Related]
38. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
39. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
[TBL] [Abstract][Full Text] [Related]
40. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
Godtfredsen NS; Jørgensen DV; Marsaa K; Ulrik CS; Andersen O; Eugen-Olsen J; Rasmussen LJH
Respir Res; 2018 May; 19(1):97. PubMed ID: 29783959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
